Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC

This study evaluated the impact of donor age on clinical outcomes in 274 patients with acute myeloid leukemia (AML) haplo-HCT using PTCY-based prophylaxis. Median patient age was 53 years, with 42.6% classified as high-risk AML. The median donor age of 38 years; 31% were under 30. An optimal donor a...

Descripción completa

Detalles Bibliográficos
Autores: Munárriz, D, Pérez-Lopez, E, Rodríguez, CM, Luque, M, Esquirol, A, Calvo, CM, Aparicio, C, Peña-Muñoz, F, Fernando, IH, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Lopez-Lorenzo, JL, Fleitas, CA, González-Rodriguez, AP, García, L, Torrado, T, Filaferro, S, Balsalobre, P, Cascon, MJP, Rovira, M, Salas, MQ
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p20789
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20789
Access Level:acceso abierto
Palabra clave:donor age
allo-HCT
haplo-HCT
PTCY
AML
id ES_ee75d5cd0e71a62028b080b9ec187f3e
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p20789
network_acronym_str ES
network_name_str España
repository_id_str
spelling Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TCMunárriz, DPérez-Lopez, ERodríguez, CMLuque, MEsquirol, ACalvo, CMAparicio, CPeña-Muñoz, FFernando, IHOrmtegi, IOMarín, AJSFernández-Luis, SDomínguez-García, JJFernández, SVLopez-Lorenzo, JLFleitas, CAGonzález-Rodriguez, APGarcía, LTorrado, TFilaferro, SBalsalobre, PCascon, MJPRovira, MSalas, MQdonor ageallo-HCThaplo-HCTPTCYAMLThis study evaluated the impact of donor age on clinical outcomes in 274 patients with acute myeloid leukemia (AML) haplo-HCT using PTCY-based prophylaxis. Median patient age was 53 years, with 42.6% classified as high-risk AML. The median donor age of 38 years; 31% were under 30. An optimal donor age cut-off of 30 years was identified through ROC analysis. Patients receiving grafts from younger donors (<30 years) showed lower rates of aGVHD grade II-IV (3.0% vs. 19.9%, p < 0.001) and grade III-IV (1.5% vs. 10.2%, p = 0.034), with no differences in cGVHD or relapse rates. Overall survival (OS) was higher in the younger donor group (2-year: 80.6% vs. 64.3%, p = 0.011), along by lower non-relapse mortality (NRM) (2-year: 11.1% vs. 23.2%, p = 0.031). Multivariate analysis confirmed donor age >= 30 years as an independent adverse factor for OS (HR: 1.88, p = 0.019) and NRM (HR: 2.06, p = 0.049), along with older recipient age, higher HCT-CI score, and high-risk AML. These findings suggest that younger donor age contributes to improved survival, primarily through reduced NRM and aGVHD, supporting prioritization of younger donors when multiple haploidentical options are available to optimize transplant outcomes.FRONTIERS MEDIA SA2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20789Frontiers in ImmunologyISSN: 16643224reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p207892026-06-14T12:41:47Z
dc.title.none.fl_str_mv Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC
title Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC
spellingShingle Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC
Munárriz, D
donor age
allo-HCT
haplo-HCT
PTCY
AML
title_short Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC
title_full Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC
title_fullStr Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC
title_full_unstemmed Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC
title_sort Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC
dc.creator.none.fl_str_mv Munárriz, D
Pérez-Lopez, E
Rodríguez, CM
Luque, M
Esquirol, A
Calvo, CM
Aparicio, C
Peña-Muñoz, F
Fernando, IH
Ormtegi, IO
Marín, AJS
Fernández-Luis, S
Domínguez-García, JJ
Fernández, SV
Lopez-Lorenzo, JL
Fleitas, CA
González-Rodriguez, AP
García, L
Torrado, T
Filaferro, S
Balsalobre, P
Cascon, MJP
Rovira, M
Salas, MQ
author Munárriz, D
author_facet Munárriz, D
Pérez-Lopez, E
Rodríguez, CM
Luque, M
Esquirol, A
Calvo, CM
Aparicio, C
Peña-Muñoz, F
Fernando, IH
Ormtegi, IO
Marín, AJS
Fernández-Luis, S
Domínguez-García, JJ
Fernández, SV
Lopez-Lorenzo, JL
Fleitas, CA
González-Rodriguez, AP
García, L
Torrado, T
Filaferro, S
Balsalobre, P
Cascon, MJP
Rovira, M
Salas, MQ
author_role author
author2 Pérez-Lopez, E
Rodríguez, CM
Luque, M
Esquirol, A
Calvo, CM
Aparicio, C
Peña-Muñoz, F
Fernando, IH
Ormtegi, IO
Marín, AJS
Fernández-Luis, S
Domínguez-García, JJ
Fernández, SV
Lopez-Lorenzo, JL
Fleitas, CA
González-Rodriguez, AP
García, L
Torrado, T
Filaferro, S
Balsalobre, P
Cascon, MJP
Rovira, M
Salas, MQ
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv donor age
allo-HCT
haplo-HCT
PTCY
AML
topic donor age
allo-HCT
haplo-HCT
PTCY
AML
description This study evaluated the impact of donor age on clinical outcomes in 274 patients with acute myeloid leukemia (AML) haplo-HCT using PTCY-based prophylaxis. Median patient age was 53 years, with 42.6% classified as high-risk AML. The median donor age of 38 years; 31% were under 30. An optimal donor age cut-off of 30 years was identified through ROC analysis. Patients receiving grafts from younger donors (<30 years) showed lower rates of aGVHD grade II-IV (3.0% vs. 19.9%, p < 0.001) and grade III-IV (1.5% vs. 10.2%, p = 0.034), with no differences in cGVHD or relapse rates. Overall survival (OS) was higher in the younger donor group (2-year: 80.6% vs. 64.3%, p = 0.011), along by lower non-relapse mortality (NRM) (2-year: 11.1% vs. 23.2%, p = 0.031). Multivariate analysis confirmed donor age >= 30 years as an independent adverse factor for OS (HR: 1.88, p = 0.019) and NRM (HR: 2.06, p = 0.049), along with older recipient age, higher HCT-CI score, and high-risk AML. These findings suggest that younger donor age contributes to improved survival, primarily through reduced NRM and aGVHD, supporting prioritization of younger donors when multiple haploidentical options are available to optimize transplant outcomes.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20789
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20789
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv Frontiers in Immunology
ISSN: 16643224
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423672694931456
score 15,81155

Similares en LA Referencia